Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Obatoclax Mesylate (GX15-070) Chemical Structure

Obatoclax Mesylate (GX15-070) Chemical Structure
Molecular Weight: 413.49

Validation & Quality Control

9 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Obatoclax Mesylate (GX15-070) is available in the following compound libraries:

Bcl-2 Inhibitors with Unique Features

  • Pan Bcl-2 Inhibitor

    ABT-737 Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

  • Most Potent Bcl-2 Inhibitor

    ABT-263 (Navitoclax) Bcl-xL, Ki≤ 0.5 nM; Bcl-2, Ki≤ 1 nM; Bcl-w, Ki≤ 1 nM.

  • Newest Bcl-2 Family Activator

    BAM7 Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • Classic Bcl-2 Inhibitor

    ABT-737 BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Product Information

  • Compare Bcl-2 Inhibitors
    Compare Bcl-2 Products
  • Research Area

Product Description

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Targets Bcl-2 [1]
(Cell-free assay)
IC50 0.22 μM(Ki)
In vitro Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KARPAS-45M2TvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGToeJdKSzVyPUCuNFAxODNzNzFOwG0>Mmj0V2FPT0WU
SK-MEL-30NVHodGtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLzZ3JKSzVyPUCuNFAxOzV3IN88US=>M3HKOXNCVkeHUh?=
NALM-6M3fENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M171O2lEPTB;MD6wNFA{PTZizszNNYHRSlB6W0GQR1XS
KYSE-450NX7Hb2ttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjxUmYzUUN3ME2wMlAxODR4OTFOwG0>MX;TRW5ITVJ?
BHYMmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPHS|VQUUN3ME2wMlAxODZyMTFOwG0>MorvV2FPT0WU
GR-STM3\pZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XxVGlEPTB;MD6wNFA3PDhizszNM2rkW3NCVkeHUh?=
786-0MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkT5TWM2OD1yLkCwNFc4PiEQvF2=NULaZ2Z6W0GQR1XS
C-33-AM3;6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvvNWtKSzVyPUCuNFAxQDR6IN88US=>NEjDd2tUSU6JRWK=
BHT-101MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HQTWlEPTB;MD6wNFExPiEQvF2=NVjtcWFVW0GQR1XS
EB2NHzOdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFOyVmZKSzVyPUCuNFAyOThizszNNHXIZVJUSU6JRWK=
G-361NHjldYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1u2VmlEPTB;MD6wNFEzPCEQvF2=MWrTRW5ITVJ?
KE-37NXGyb4xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojJTWM2OD1yLkCwNVI5KM7:TR?=MnnmV2FPT0WU
MHH-PREB-1NF\xd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTBwMECxOEDPxE1?MmTaV2FPT0WU
MCF7NVX2flFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\mTWM2OD1yLkCwNVU6KM7:TR?=NVfOdXZWW0GQR1XS
LOUCYMk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXyTWM2OD1yLkCwNVc2KM7:TR?=NFX0fIxUSU6JRWK=
EW-7MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;wTWM2OD1yLkCwNVc2KM7:TR?=NWDCfWxNW0GQR1XS
KYSE-510MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjoTWM2OD1yLkCwNlM{KM7:TR?=NInsWZhUSU6JRWK=
SK-MEL-3MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zOVGlEPTB;MD6wNFI3PCEQvF2=NHHKZ|ZUSU6JRWK=
HAL-01NX34RWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPu[IlxUUN3ME2wMlAxOjl5IN88US=>M3TCc3NCVkeHUh?=
HCC2998MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTBwMECzN|Uh|ryPMV7TRW5ITVJ?
A375MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXZT2tKSzVyPUCuNFA{PSEQvF2=NWq0[IY3W0GQR1XS
MZ7-melMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPpTWM2OD1yLkCwN|k6KM7:TR?=MX\TRW5ITVJ?
SH-4Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTW[HJ7UUN3ME2wMlAxPDF5IN88US=>MVjTRW5ITVJ?
HT-144M2nnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVz2SmJWUUN3ME2wMlAxPDNizszNM13HWnNCVkeHUh?=
KYSE-140MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jYWGlEPTB;MD6wNFQ{PSEQvF2=MXjTRW5ITVJ?
PSN1MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYT5TWMxUUN3ME2wMlAxPDZ5IN88US=>NIDwWotUSU6JRWK=
COLO-679M4S5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTzUpZKSzVyPUCuNFA1QThizszNNXzNeYFqW0GQR1XS
SW620NHXJb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTBwMEC1NVEh|ryPM4DofnNCVkeHUh?=
HGC-27MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPrc4FKSzVyPUCuNFA2OjRizszNMln6V2FPT0WU
IGROV-1NHO4VHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TiUGlEPTB;MD6wNFYh|ryPMmq5V2FPT0WU
IGR-1NXXQd5lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPiTWM2OD1yLkCwOlAyKM7:TR?=Mo[wV2FPT0WU
EW-1NGrKWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXtTWM2OD1yLkCwOlUyKM7:TR?=NYXuW4drW0GQR1XS
769-PNXO5[FY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;TU2lEPTB;MD6wNFY4QCEQvF2=NFftbGVUSU6JRWK=
HNNWXBfZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHMTWM2OD1yLkCwOlc6KM7:TR?=MWXTRW5ITVJ?
SIG-M5NED6U4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDjfFhKSzVyPUCuNFA4OSEQvF2=NEWwXWRUSU6JRWK=
IST-MEL1MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwMEC4NVgh|ryPM1;CZ3NCVkeHUh?=
ST486NXS5elE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHPTWM2OD1yLkCwPFI2KM7:TR?=MlPKV2FPT0WU
ES7NWTD[|RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTmTWM2OD1yLkCwPFQ3KM7:TR?=MmLOV2FPT0WU
GAKNVnEXWsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInsVmVKSzVyPUCuNFA5PDhizszNNIXUVYNUSU6JRWK=
BB30-HNCMm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPCW4pKSzVyPUCuNFA5PThizszNNFfDcHpUSU6JRWK=
IPC-298M4nscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\XT2lEPTB;MD6wNFkzPyEQvF2=NGL5NnpUSU6JRWK=
NKM-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmP4TWM2OD1yLkCwPVczKM7:TR?=M{jE[nNCVkeHUh?=
RKOMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnhW2FMUUN3ME2wMlAyODR2IN88US=>MYfTRW5ITVJ?
ACNNUXTTnh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTIWVZUUUN3ME2wMlAyOTNzIN88US=>MVPTRW5ITVJ?
SW1417NFm0bpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfNTWM2OD1yLkCxNlI2KM7:TR?=M2fWPXNCVkeHUh?=
SRNETmWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDoenpKSzVyPUCuNFEzOzVizszNNHq2OpVUSU6JRWK=
SNG-MM2XsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfz[2d4UUN3ME2wMlAyOzF5IN88US=>M33nOHNCVkeHUh?=
CAL-12TMnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTBwMEGzOFYh|ryPNFW3[FVUSU6JRWK=
HSC-3MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXkTWM2OD1yLkCxN|U2KM7:TR?=NYDPVFBUW0GQR1XS
DOHH-2M3:4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvyZnR2UUN3ME2wMlAyPDF{IN88US=>M33SXHNCVkeHUh?=
NB69MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LEfGlEPTB;MD6wNVU3PSEQvF2=MnnCV2FPT0WU
LC-2-adM1vXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\MZoRKSzVyPUCuNFE2QDFizszNNVnzSnZSW0GQR1XS
RVH-421M1fXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{foV2lEPTB;MD6wNVY4PCEQvF2=M1vzdXNCVkeHUh?=
TGWMmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXwSnNGUUN3ME2wMlAyPzN7IN88US=>NX63PYp{W0GQR1XS
HCC1569NXTqOpl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XTfGlEPTB;MD6wNVc6PyEQvF2=NGHDZlhUSU6JRWK=
CAL-85-1NGKzNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULZOYdzUUN3ME2wMlAyQDN{IN88US=>MlHJV2FPT0WU
RPMI-8402MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M374OGlEPTB;MD6wNVg2QCEQvF2=MoDQV2FPT0WU
THP-1NYTQWplYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTBwMEG5PVgh|ryPMUPTRW5ITVJ?
ONS-76M4nKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPMTWM2OD1yLkCyNFM3KM7:TR?=MYDTRW5ITVJ?
A2780MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTBwMEKwO|kh|ryPNWnpUotkW0GQR1XS
RPMI-2650M3HWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTBwMEKyPVYh|ryPM3W4WXNCVkeHUh?=
MEL-HOMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zGe2lEPTB;MD6wNlM1QCEQvF2=NHK0OI9USU6JRWK=
MC-CARMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnHW4RQUUN3ME2wMlAzOzV4IN88US=>Mn\xV2FPT0WU
HSC-2M1HnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlexTWM2OD1yLkCyOFY3KM7:TR?=MlXMV2FPT0WU
MEL-JUSOMnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWL6UZVWUUN3ME2wMlAzPDd|IN88US=>MlPpV2FPT0WU
CAL-62Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwMEK2NFIh|ryPNUfMeG15W0GQR1XS
DMS-273MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnac2RKSzVyPUCuNFI5PDdizszNMUHTRW5ITVJ?
S-117NXjQcWd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jJWWlEPTB;MD6wNlkxPiEQvF2=NH;pOlRUSU6JRWK=
SUP-T1MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{O0dGlEPTB;MD6wNlk1QSEQvF2=MkThV2FPT0WU
MZ2-MELNVHUOVF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fCS2lEPTB;MD6wNlk2QSEQvF2=MYrTRW5ITVJ?
KYSE-270NVPUbo53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vSWGlEPTB;MD6wNlk4PiEQvF2=MYPTRW5ITVJ?
CMKMlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTBwMEOwNlMh|ryPMVvTRW5ITVJ?
8505CNXHzSVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjxN49KSzVyPUCuNFMxPCEQvF2=NITWToxUSU6JRWK=
NUGC-3NV7U[FJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETUW4lKSzVyPUCuNFMxPDhizszNMnnDV2FPT0WU
A101DNVXo[YhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGWxS5BKSzVyPUCuNFMxPTVizszNNV3aSJVmW0GQR1XS
G-401MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXHdGNpUUN3ME2wMlA{ODl|IN88US=>MoH4V2FPT0WU
OVCAR-8NYr3dXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPTTWM2OD1yLkCzNVA4KM7:TR?=MWfTRW5ITVJ?
IMR-5NY\YOpdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTBwMEOyOFQh|ryPMoPvV2FPT0WU
DoTc2-4510MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3ndnY6UUN3ME2wMlA{Ozl|IN88US=>MXLTRW5ITVJ?
HOSMlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTBwMEO0O|Mh|ryPMmXxV2FPT0WU
HEC-1M2OzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwMEO2PEDPxE1?NUDvb4ltW0GQR1XS
SW756MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDhXXpZUUN3ME2wMlA{QDJzIN88US=>NF7xTW9USU6JRWK=
NCI-H64MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELUVWRKSzVyPUCuNFM5PDJizszNNGfSSoVUSU6JRWK=
EW-16MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrZfJNZUUN3ME2wMlA{QTB7IN88US=>NFq3VGxUSU6JRWK=
CAL-51Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\LTWM2OD1yLkC0NFA2KM7:TR?=MV;TRW5ITVJ?
KYSE-150M2LXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwMESwNVEh|ryPNYjGcZN5W0GQR1XS
SW1710MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTvTWM2OD1yLkC0NFE5KM7:TR?=NGrCZYFUSU6JRWK=
HuP-T4M4ThXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jINmlEPTB;MD6wOFEyQCEQvF2=NGHoVHVUSU6JRWK=
LB373-MEL-DM{KyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\LTWM2OD1yLkC0NlMzKM7:TR?=MWfTRW5ITVJ?
EW-13M{jsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLqTWM2OD1yLkC0OFA3KM7:TR?=MVLTRW5ITVJ?
HT-29NVH2eo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHUTWM2OD1yLkC0OFkh|ryPNXXQeot5W0GQR1XS
SCC-25M4qw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrQSm9KSzVyPUCuNFQ1QTRizszNNH\qdVdUSU6JRWK=
REHMk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{i5cWlEPTB;MD6wOFY{PSEQvF2=MXvTRW5ITVJ?
L-363NX3xPIVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3T2fGlEPTB;MD6wOFY4QSEQvF2=NILGXmdUSU6JRWK=
NCI-H1770Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\pTWM2OD1yLkC0Olk4KM7:TR?=NVzLdIhlW0GQR1XS
CHL-1NFrBUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF:5dIlKSzVyPUCuNFQ5PTdizszNNHna[HNUSU6JRWK=
ES1NW\QTpc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUH1WmNlUUN3ME2wMlA1QDh3IN88US=>MnnFV2FPT0WU
SCC-15NF\0VlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\BTWM2OD1yLkC0PVAzKM7:TR?=M1XoUnNCVkeHUh?=
MRK-nu-1NFi0cmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrOWodFUUN3ME2wMlA1QTN4IN88US=>NV\jTlVSW0GQR1XS
PF-382MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjJTWM2OD1yLkC0PVM6KM7:TR?=NFn0WWpUSU6JRWK=
COLO-680NNEP5R3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLaOWxKSzVyPUCuNFUxPDdizszNNWexeHBDW0GQR1XS
LK-2MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\BRmlEPTB;MD6wOVA3OyEQvF2=NFP1cYNUSU6JRWK=
NCI-H2342Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTBwMEWxNVch|ryPNITadmZUSU6JRWK=
HMV-IINX\LNJVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTBwMEWyN|kh|ryPM2nRdnNCVkeHUh?=
PC-14M17nNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7YfVV3UUN3ME2wMlA2OjV{IN88US=>MnnzV2FPT0WU
COLO-320-HSRNI[3PVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnNTIFKSzVyPUCuNFUzQDlizszNM3HFO3NCVkeHUh?=
697Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vpcGlEPTB;MD6wOVMzOyEQvF2=NEDEOZdUSU6JRWK=
NEC8MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\aTWM2OD1yLkC1OVkh|ryPMlH2V2FPT0WU
LCLC-97TM1NVv0[3FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFj6dJBKSzVyPUCuNFU2QTRizszNMm\yV2FPT0WU
DaoyNWjJ[3ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXq2WJZpUUN3ME2wMlA2PjF4IN88US=>M{DkT3NCVkeHUh?=
ETK-1NXHveXRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3OzZmlEPTB;MD6wOVY4OiEQvF2=M33LTHNCVkeHUh?=
A388MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;CTWM2OD1yLkC1Olk2KM7:TR?=MV\TRW5ITVJ?
COLO-205MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDCWmJJUUN3ME2wMlA2PzF4IN88US=>Mm\5V2FPT0WU
SK-PN-DWMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zGSmlEPTB;MD6wOVczQSEQvF2=NYLkd|FPW0GQR1XS
SF268M2jaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTBwMEW3OVYh|ryPM{WycXNCVkeHUh?=
OCI-AML2NI\LNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTBwMEW3O|ch|ryPMmDLV2FPT0WU
GAMGM{TKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjyTWM2OD1yLkC1PEDPxE1?MUPTRW5ITVJ?
BCPAPMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHoVmlKSzVyPUCuNFU5QTJizszNMmXuV2FPT0WU
BC-1NGDkWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoOyTWM2OD1yLkC2NFIzKM7:TR?=M{PBcHNCVkeHUh?=
IA-LMM1fWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nkNGlEPTB;MD6wOlA2OyEQvF2=NHvYfIJUSU6JRWK=
NCI-H1299NHrER4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zlcGlEPTB;MD6wOlE{KM7:TR?=NV\KO3h4W0GQR1XS
COR-L23MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoC5TWM2OD1yLkC2NVM1KM7:TR?=M3TnOnNCVkeHUh?=
KYSE-180NFzZeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPVTWM2OD1yLkC2NVQzKM7:TR?=Ml2wV2FPT0WU
LOXIMVIMm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInITGxKSzVyPUCuNFYyQDhizszNM1uzVHNCVkeHUh?=
BL-41MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnY[mVLUUN3ME2wMlA3OjF7IN88US=>MlHYV2FPT0WU
BL-70NEjlUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{D2UWlEPTB;MD6wOlMxOiEQvF2=NEjnNWZUSU6JRWK=
NOS-1Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjZcphKSzVyPUCuNFY1OTFizszNMnnBV2FPT0WU
NB13NGDR[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX:2TG5JUUN3ME2wMlA3PDJzIN88US=>NF;PWnVUSU6JRWK=
CAL-27NEDzOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[wUpNSUUN3ME2wMlA3PDZ2IN88US=>Ml2wV2FPT0WU
CA46MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTBwME[1N|ch|ryPNV7YSJRYW0GQR1XS
SW962MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTBwME[1Olkh|ryPMYDTRW5ITVJ?
NCI-H226NEfkWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTBwME[2N|Ih|ryPNGi0eGdUSU6JRWK=
KYSE-70MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHWTWM2OD1yLkC2PVQ2KM7:TR?=M1vBdXNCVkeHUh?=
DaudiMl7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTwTWM2OD1yLkC3NFgyKM7:TR?=NVLRPGRIW0GQR1XS
SW626NVuxeXhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfSdXNKSzVyPUCuNFczODRizszNNYHSSG06W0GQR1XS
ESS-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTBwMEeyOFYh|ryPNXK4R4REW0GQR1XS
YTMnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXBN2hKSzVyPUCuNFc{PDVizszNM{HyWnNCVkeHUh?=
P12-ICHIKAWAMkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn2yTWM2OD1yLkC3N|Q6KM7:TR?=MYDTRW5ITVJ?
BxPC-3M4Kxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwMEe0OVgh|ryPMnXEV2FPT0WU
CTV-1NX\aXJA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NET1ZWRKSzVyPUCuNFc2OTdizszNMo\uV2FPT0WU
MLMANYi1[ZByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTBwMEe1N|Qh|ryPMVzTRW5ITVJ?
WSU-NHLM{mwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjaTWM2OD1yLkC3OVU1KM7:TR?=MmPCV2FPT0WU
CTB-1MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTBwMEe1PFgh|ryPM1f1WnNCVkeHUh?=
MMAC-SFNUXwS2pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\yTWM2OD1yLkC3OlY5KM7:TR?=NFPvO3hUSU6JRWK=
8-MG-BAM4n2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlntTWM2OD1yLkC3PFAyKM7:TR?=MXLTRW5ITVJ?
NCI-H358NUnSZ|hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\GTWM2OD1yLkC3PFc6KM7:TR?=MYHTRW5ITVJ?
BFTC-905M{\2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfXToJGUUN3ME2wMlA4QTB7IN88US=>MUHTRW5ITVJ?
NCI-H727MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWL1fod4UUN3ME2wMlA5ODV|IN88US=>MnfIV2FPT0WU
CHP-212MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVO4N3J5UUN3ME2wMlA5ODl3IN88US=>M4WxTHNCVkeHUh?=
HOP-62NIq5[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrnUnNNUUN3ME2wMlA5OjR3IN88US=>NIflOY5USU6JRWK=
CESSMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfSRlZMUUN3ME2wMlA5OjZ7IN88US=>NYnkNpJzW0GQR1XS
HuCCT1NGTPUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnYTWM2OD1yLkC4N|M{KM7:TR?=MX\TRW5ITVJ?
DELMnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTBwMEizOFch|ryPNHT4OXNUSU6JRWK=
5637M1H4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTBwMEizOlch|ryPMXXTRW5ITVJ?
RS4-11M3PtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoW5TWM2OD1yLkC4OFk4KM7:TR?=NWj1cJNSW0GQR1XS
KURAMOCHIMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPKTWM2OD1yLkC4OVA6KM7:TR?=NWfieXFFW0GQR1XS
A427NED2WpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfj[HFvUUN3ME2wMlA5PTF{IN88US=>NFjZOWVUSU6JRWK=
A3-KAWNXn4SGhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUGwPXNTUUN3ME2wMlA5PTZ4IN88US=>M2CxcnNCVkeHUh?=
LS-123NYXqOWVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXuTWM2OD1yLkC4O|E6KM7:TR?=NWrhc5JqW0GQR1XS
LoVoNFLXZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3s[XM1UUN3ME2wMlA5PzJizszNMk\xV2FPT0WU
PA-1NUDsNo5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjvTWM2OD1yLkC4O|Y6KM7:TR?=M{XZdXNCVkeHUh?=
CP50-MEL-BNF7Fc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zTWmlEPTB;MD6wPFc6OyEQvF2=MljkV2FPT0WU
A431NX6xO|djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;NV5VKSzVyPUCuNFg5ODFizszNNU\ScHNXW0GQR1XS
HCT-116M1i3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\lTWM2OD1yLkC4PFAzKM7:TR?=NGe1O3lUSU6JRWK=
A4-FukNIDMb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTBwMEi5OFch|ryPNYHvOFJjW0GQR1XS
RPMI-6666MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHzZ3ZnUUN3ME2wMlA5QTZ5IN88US=>NHruXFhUSU6JRWK=
Calu-6NIO0cHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7UOVFxUUN3ME2wMlA6ODJ7IN88US=>MY\TRW5ITVJ?
KMOE-2Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoW1TWM2OD1yLkC5NFM6KM7:TR?=MWrTRW5ITVJ?
A704M133NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7uTWM2OD1yLkC5NVUh|ryPNGXlVotUSU6JRWK=
HO-1-N-1M3zhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnX2TWM2OD1yLkC5NlQ6KM7:TR?=MnrlV2FPT0WU
NCI-H2122NVvBPY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLITWM2OD1yLkC5N|c5KM7:TR?=MXXTRW5ITVJ?
U-698-MNIHZRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITU[olKSzVyPUCuNFk1ODlizszNMVLTRW5ITVJ?
IST-SL2NYnIeYZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTwOJpnUUN3ME2wMlA6PDZ6IN88US=>NXLSVpJQW0GQR1XS
TE-10NYfiW5RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHRUHNKSzVyPUCuNFk2QDRizszNMYPTRW5ITVJ?
PANC-03-27MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHMTWM2OD1yLkC5OlcyKM7:TR?=M{nVbXNCVkeHUh?=
KYSE-410MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\MfYc2UUN3ME2wMlA6Pzl5IN88US=>NYS1NmltW0GQR1XS
TE-8NIn6bZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fKfGlEPTB;MD6wPVg5PSEQvF2=NGG3[WhUSU6JRWK=
MN-60MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTBwMEm4PVch|ryPMnrsV2FPT0WU
NCI-H460NVP6V5BwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LFR2lEPTB;MD6xNFA6KM7:TR?=MlvxV2FPT0WU
LB771-HNCM{TDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\BUWlEPTB;MD6xNFI2PSEQvF2=MlPaV2FPT0WU
ES4NWDMXoJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLDTWM2OD1yLkGwNlY1KM7:TR?=NH;y[|VUSU6JRWK=
HUTU-80MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHCeVNKSzVyPUCuNVA{PjVizszNNX;SWmdXW0GQR1XS
647-VNF3nUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPlW3RKSzVyPUCuNVA1ODhizszNMnfEV2FPT0WU
HTC-C3NWP5dlB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPhPG9KSzVyPUCuNVA1OzJizszNMmWwV2FPT0WU
NTERA-S-cl-D1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13obGlEPTB;MD6xNFQ1QCEQvF2=NW\HPJp3W0GQR1XS
A2058MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLFRYdyUUN3ME2wMlExPjV3IN88US=>MUfTRW5ITVJ?
MZ1-PCMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHp[HpKSzVyPUCuNVA5OyEQvF2=NYG4T45uW0GQR1XS
J82MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\3OmdNUUN3ME2wMlExQDh2IN88US=>MlGzV2FPT0WU
ARH-77MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHGTWM2OD1yLkGxJO69VQ>?MUXTRW5ITVJ?
Ca9-22MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYft[JBPUUN3ME2wMlEyOTJ6IN88US=>MV\TRW5ITVJ?
NCI-H1648MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHnZ3FKSzVyPUCuNVEzQDZizszNMYXTRW5ITVJ?
MC116NF;pc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfjRlVIUUN3ME2wMlEyOzN5IN88US=>MWTTRW5ITVJ?
EoL-1-cellM2jjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEe1[|dKSzVyPUCuNVE1PjdizszNNXjvUVltW0GQR1XS
PANC-10-05NHy5R2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jaXmlEPTB;MD6xNVQ6OSEQvF2=MXHTRW5ITVJ?
SF539MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvYTWM2OD1yLkGxOlE3KM7:TR?=NHnoU2JUSU6JRWK=
ES8NUSzOZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DxXmlEPTB;MD6xNVY{OyEQvF2=M{fCW3NCVkeHUh?=
NCI-H810NH23VZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTBwMUG2OlQh|ryPMmnJV2FPT0WU
J-RT3-T3-5NVzJS241T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzQTWM2OD1yLkGxO|Uh|ryPNGDjSoZUSU6JRWK=
NYMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHOO3JKSzVyPUCuNVE5OTdizszNM2LzSHNCVkeHUh?=
NCI-SNU-1Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPSWnZTUUN3ME2wMlEzOTR6IN88US=>NXXyZ2lRW0GQR1XS
EFM-19M4jGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXpOJZoUUN3ME2wMlEzOzd2IN88US=>M4TGOXNCVkeHUh?=
HCC1806MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHpSFdMUUN3ME2wMlEzOzh|IN88US=>MnLTV2FPT0WU
HCE-TNFGxV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TPUmlEPTB;MD6xNlU{OSEQvF2=NFzSPXVUSU6JRWK=
HT-1376MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vmNWlEPTB;MD6xNlY3QCEQvF2=NHjYVGtUSU6JRWK=
BE-13MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTBwMUK4OlYh|ryPM{W4PHNCVkeHUh?=
NCI-H520MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fHNmlEPTB;MD6xNlg3PyEQvF2=MUjTRW5ITVJ?
SK-MES-1M3zjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XwcmlEPTB;MD6xNlkyOyEQvF2=MYrTRW5ITVJ?
SNU-423NUTiVlQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13jfWlEPTB;MD6xNlkyPCEQvF2=NFrFdGJUSU6JRWK=
Ramos-2G6-4C10M4P4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4roeGlEPTB;MD6xNlkyPiEQvF2=NIfpU2ZUSU6JRWK=
EW-18MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmO2TWM2OD1yLkGzNFI3KM7:TR?=NGrjZ5FUSU6JRWK=
NCI-H2087MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTBwMUOwNlch|ryPMkDnV2FPT0WU
COLO-792MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTBwMUOxOlUh|ryPMmqyV2FPT0WU
QIMR-WILMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFm1c2dKSzVyPUCuNVMzOjNizszNMV\TRW5ITVJ?
ACHNMmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3ubGZKSzVyPUCuNVMzPDdizszNNWrUT|BPW0GQR1XS
RPMI-8866NXTIWWpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnjXZA4UUN3ME2wMlE{OjZzIN88US=>NE[xRYZUSU6JRWK=
SK-LU-1MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;zNmhFUUN3ME2wMlE{PDR7IN88US=>M{nFcHNCVkeHUh?=
SK-UT-1NF\XO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojKTWM2OD1yLkGzOlI5KM7:TR?=MWPTRW5ITVJ?
MFE-296NUHqXHFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjsT5lKSzVyPUCuNVM5PjRizszNMWDTRW5ITVJ?
RDNFXVeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M331dWlEPTB;MD6xN|k6PyEQvF2=MWLTRW5ITVJ?
LS-411NMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoK1TWM2OD1yLkG0Nlk2KM7:TR?=MVHTRW5ITVJ?
NCI-H747NUG2ZmZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTBwMUSzJO69VQ>?MkLQV2FPT0WU
ES6MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTBwMUSzOkDPxE1?M1H1ZnNCVkeHUh?=
TE-1M{DrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfJTWM2OD1yLkG0OFA4KM7:TR?=Mm\qV2FPT0WU
SJSA-1NXHYUnlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTBwMUS3NFch|ryPNFHIN2lUSU6JRWK=
NCI-H1355M2HxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTBwMUWyPVMh|ryPMXjTRW5ITVJ?
HELNXj3dm1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\OXWlEPTB;MD6xOVQ1PyEQvF2=NUH1PGE3W0GQR1XS
639-VNX\pemJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml36TWM2OD1yLkG1OVk3KM7:TR?=NHjXdm5USU6JRWK=
AN3-CANG[3SYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjhSoFTUUN3ME2wMlE2PjN7IN88US=>NHXUfpNUSU6JRWK=
SK-MEL-2MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HZU2lEPTB;MD6xOVY3QCEQvF2=M2mxN3NCVkeHUh?=
SW872NV23dXVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFeyenFKSzVyPUCuNVYxPDJizszNMVfTRW5ITVJ?
DU-4475M3fyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXmTWM2OD1yLkG2NVYzKM7:TR?=NFvW[IdUSU6JRWK=
YKG-1M1GxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV2wfZFYUUN3ME2wMlE3Ojd|IN88US=>Mk\PV2FPT0WU
GT3TKBNYjvWnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTBwMU[yPFMh|ryPMWPTRW5ITVJ?
GB-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTBwMU[0NlQh|ryPMVTTRW5ITVJ?
KARPAS-422NFzico1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITFVmZKSzVyPUCuNVY2PzRizszNM3LydXNCVkeHUh?=
ATN-1NWf0WVJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXZTWM2OD1yLkG2OlU3KM7:TR?=MX3TRW5ITVJ?
HLEMnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXRem9KSzVyPUCuNVY5PzdizszNMWPTRW5ITVJ?
D-542MGM37JN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3ITWM2OD1yLkG2PVg3KM7:TR?=NIq5UWNUSU6JRWK=
EB-3NEXoWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;qe5M{UUN3ME2wMlE4OzFizszNMlLvV2FPT0WU
HCC1143MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFP3NZdKSzVyPUCuNVc{QTZizszNMl3tV2FPT0WU
DJM-1M4XVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\jU|RKSzVyPUCuNVc1PTFizszNMl64V2FPT0WU
BT-474NFrJeoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTBwMUe0PFkh|ryPMmizV2FPT0WU
BB65-RCCNIfGfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo[zTWM2OD1yLkG3OVQ2KM7:TR?=NXyxSmwxW0GQR1XS
NCI-H292NVjpeoE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTBwMUe2NFEh|ryPNWHmXXh7W0GQR1XS
MKN28NVvyZ|B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4KwNWlEPTB;MD6xO|Y2OyEQvF2=MmHHV2FPT0WU
TK10NHTJeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHHO3NKSzVyPUCuNVc4ODJizszNNWr5UHlSW0GQR1XS
TYK-nuNGGyZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTBwMUe5OFkh|ryPNWnOWooyW0GQR1XS
8305CNHL1c5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nvV2lEPTB;MD6xO|k4OSEQvF2=NULlUHF4W0GQR1XS
MV-4-11NFv3coVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nXfGlEPTB;MD6xO|k4PyEQvF2=M2fNbXNCVkeHUh?=
NCI-H522NGPHdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnvTWM2OD1yLkG4NFk1KM7:TR?=NHe0W4lUSU6JRWK=
Hs-578-TMljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTBwMUiyPVIh|ryPNF7Vc3BUSU6JRWK=
LCLC-103HMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnE[VhWUUN3ME2wMlE5PTJ5IN88US=>NV\YS3R6W0GQR1XS
MHH-ES-1NF;ObodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3faeGlEPTB;MD6xPFYzQSEQvF2=NFq1SWtUSU6JRWK=
NCI-H441NF7OV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnoNGVKSzVyPUCuNVkyPDhizszNMmm3V2FPT0WU
AM-38NWTURlVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYn2WmxiUUN3ME2wMlE6OjJ3IN88US=>NYLCTXV[W0GQR1XS
SW1783MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTBwMUmzNFUh|ryPNEHjbYRUSU6JRWK=
SK-HEP-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHz5ephKSzVyPUCuNVk3OzdizszNMX\TRW5ITVJ?
OAW-28MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;uWWlEPTB;MD6yNFE4QCEQvF2=NFP4ZlBUSU6JRWK=
TE-15NFPOWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XoWWlEPTB;MD6yNFI2OiEQvF2=NGmyOYVUSU6JRWK=
HCE-4MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXRTWM2OD1yLkKwNlg1KM7:TR?=M3TmbnNCVkeHUh?=
JiyoyeP-2003M{noeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTBwMkCzN|Yh|ryPMlH6V2FPT0WU
OVCAR-4NUXwfo0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfvc4pKUUN3ME2wMlIxPjJ6IN88US=>NHX5cmZUSU6JRWK=
SNU-449MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmW2TWM2OD1yLkKwO|k4KM7:TR?=NW\Ee3JuW0GQR1XS
SBC-5NH[5OnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3VTWFKSzVyPUCuNlEzOTVizszNM4fOb3NCVkeHUh?=
T84MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYm2eml3UUN3ME2wMlIyOjR6IN88US=>M2HQ[XNCVkeHUh?=
LP-1M4n3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwMkGzNFIh|ryPM1j4UHNCVkeHUh?=
MG-63NHewbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTBwMkGzPFIh|ryPM4HMT3NCVkeHUh?=
OAW-42MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTBwMkG0O|gh|ryPNIXiTXZUSU6JRWK=
L-540NV3VTVgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M12wb2lEPTB;MD6yNVU6QCEQvF2=MkP5V2FPT0WU
RH-1MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwMkKyOFIh|ryPNFP2cFVUSU6JRWK=
HCT-15MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\KeIlmUUN3ME2wMlIzPDh2IN88US=>MYLTRW5ITVJ?
OCUB-MM17BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTBwMkK0PFgh|ryPMmjuV2FPT0WU
GP5dNVzHUlY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUGwSFhQUUN3ME2wMlIzPTJ6IN88US=>MVnTRW5ITVJ?
NCI-H2030MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PUfGlEPTB;MD6yNlc{PCEQvF2=M1HnSnNCVkeHUh?=
ML-2NHfHfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DqdGlEPTB;MD6yNlg5QSEQvF2=MnjnV2FPT0WU
CAL-39NYjx[o97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnCTG1{UUN3ME2wMlIzQTN4IN88US=>MXnTRW5ITVJ?
MIA-PaCa-2M3LhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PqeWlEPTB;MD6yN|I5PyEQvF2=NH3DcYxUSU6JRWK=
TE-9M4fHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTBwMkOzNkDPxE1?M1LmOnNCVkeHUh?=
LB2518-MELMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYO5PIh6UUN3ME2wMlI{Ozd{IN88US=>MW\TRW5ITVJ?
DBM17nSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfCTWM2OD1yLkKzOFM5KM7:TR?=M3jHd3NCVkeHUh?=
NCI-H596MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYT3boxtUUN3ME2wMlI{PTdzIN88US=>MXvTRW5ITVJ?
SW1990MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEWwTmRKSzVyPUCuNlM6PDZizszNM2DETHNCVkeHUh?=
P30-OHKNGHG[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrYe|VmUUN3ME2wMlI1ODVizszNMULTRW5ITVJ?
ALL-POMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTBwMkSxOlkh|ryPMVrTRW5ITVJ?
Saos-2MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTBwMkS1O|Eh|ryPMlX1V2FPT0WU
MFH-inoMoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTBwMkS2PVIh|ryPNH\lOJFUSU6JRWK=
OE33NFrMSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DnTWlEPTB;MD6yOVEyKM7:TR?=M{LSUHNCVkeHUh?=
Calu-3NF3T[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLk[5VPUUN3ME2wMlI2Ojl5IN88US=>NVPEeI9HW0GQR1XS
HTMmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\JWHdKSzVyPUCuNlU3OjFizszNMkPtV2FPT0WU
LXF-289NEnVcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfXW|ZTUUN3ME2wMlI2QTh2IN88US=>NUn5SFIzW0GQR1XS
KGNNVjrTJR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPFPIZ1UUN3ME2wMlI3ODh7IN88US=>NX;XV3BkW0GQR1XS
NCI-H1417MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XhfGlEPTB;MD6yOlUzPCEQvF2=NWXHOlFQW0GQR1XS
SF126MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1GxZmlEPTB;MD6yO|MxOiEQvF2=Mn;LV2FPT0WU
SASMk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYL1TpJzUUN3ME2wMlI4OzB6IN88US=>NI\zPWlUSU6JRWK=
22RV1NF7vdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHDfmhuUUN3ME2wMlI4Ozd6IN88US=>M323U3NCVkeHUh?=
GI-1NEfyVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3n0VmlEPTB;MD6yO|Q5PyEQvF2=M1r6OHNCVkeHUh?=
ES3Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHT3cG9KSzVyPUCuNlc4PjNizszNMo\hV2FPT0WU
NB1MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PnSWlEPTB;MD6yO|g4PiEQvF2=NEG0R4NUSU6JRWK=
NCI-H650MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nTSmlEPTB;MD6yPFMxOiEQvF2=MnzKV2FPT0WU
IST-MES1NUS0VXpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XCZWlEPTB;MD6yPFU2PCEQvF2=MmH3V2FPT0WU
UM-UC-3Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zC[2lEPTB;MD6yPVE1KM7:TR?=NFXxU5RUSU6JRWK=
CAL-120Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTBwMkm2N|Eh|ryPMkPBV2FPT0WU
UACC-62NYXBOoN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTBwM{CyOFEh|ryPM3vjT3NCVkeHUh?=
TE-11MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nZWWlEPTB;MD6zNFI1QSEQvF2=NUTPR|hYW0GQR1XS
MKN1Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3OUmJKSzVyPUCuN|A{PiEQvF2=NEHpSXBUSU6JRWK=
KS-1M4PUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTZTWM2OD1yLkOwOVI3KM7:TR?=NF;DTIZUSU6JRWK=
GCIYNWHwfnJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkj6TWM2OD1yLkOxNFAzKM7:TR?=NVKwZXVoW0GQR1XS
OVCAR-5M33T[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfQXXFKSzVyPUCuN|EyODZizszNNFH2bVFUSU6JRWK=
U-266NYDxXnE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnX0TWM2OD1yLkOxNVQ4KM7:TR?=MmTRV2FPT0WU
Calu-1MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkX2TWM2OD1yLkOxNlg6KM7:TR?=NVro[3lPW0GQR1XS
SK-LMS-1NYD0R4NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnS2TWM2OD1yLkOxOFI6KM7:TR?=NEXuSoZUSU6JRWK=
COLO-741NH;nOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2mxb2lEPTB;MD6zNVYyPCEQvF2=M{fQTHNCVkeHUh?=
RPMI-8226NX7NTYdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXiwdFdkUUN3ME2wMlMyPjRzIN88US=>NFnmOIxUSU6JRWK=
KM12NXrPWHl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTBwM{G4N{DPxE1?MY\TRW5ITVJ?
NMC-G1M3L6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGO2e5BKSzVyPUCuN|E5PiEQvF2=MlHOV2FPT0WU
SJRH30Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXy[JZRUUN3ME2wMlMzODV{IN88US=>NWj5Wo5PW0GQR1XS
COR-L105MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTBwM{KyNVgh|ryPNUT5XZl3W0GQR1XS
IM-9NU[zNHVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LHV2lEPTB;MD6zN|AzOSEQvF2=NYi4dpd6W0GQR1XS
TE-12MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTETWM2OD1yLkOzN|E4KM7:TR?=NWHhdnZtW0GQR1XS
KG-1NGCzR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HtfGlEPTB;MD6zN|Q{OiEQvF2=MYLTRW5ITVJ?
U251MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTBwM{O0OVYh|ryPNIS0fIlUSU6JRWK=
EFO-27M1zuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fnVGlEPTB;MD6zN|k2OSEQvF2=MmraV2FPT0WU
EW-24MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnniTWM2OD1yLkOzPVg1KM7:TR?=MWLTRW5ITVJ?
SF295NITPbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPW[Gt2UUN3ME2wMlM{QTl7IN88US=>NXLiN2hHW0GQR1XS
MC-IXCMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHUZZRKSzVyPUCuN|Q2KM7:TR?=MmO1V2FPT0WU
NCI-H2405NUXlXG12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTBwM{S3N|Ih|ryPMn7pV2FPT0WU
NCI-H2009MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mor1TWM2OD1yLkO0O|M6KM7:TR?=MnvCV2FPT0WU
LB1047-RCCMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFz5O|NKSzVyPUCuN|U5OTVizszNMXzTRW5ITVJ?
KNS-81-FDNW\mVWFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33mb2lEPTB;MD6zOlY3PyEQvF2=M{j3THNCVkeHUh?=
HOP-92MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nUPGlEPTB;MD6zOlg{KM7:TR?=M4mzZXNCVkeHUh?=
L-428NEDnXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITZXoxKSzVyPUCuN|cxOTZizszNNFnGR|FUSU6JRWK=
C3AMlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnuTWM2OD1yLkO3N|c6KM7:TR?=NGnveZNUSU6JRWK=
NCI-H1792NGjYc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXyyeopPUUN3ME2wMlM4PjV3IN88US=>MWPTRW5ITVJ?
HuH-7MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TUfmlEPTB;MD6zO|kyKM7:TR?=NGnjbGdUSU6JRWK=
AGSMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3W5RmlEPTB;MD6zPFY{QCEQvF2=Mm[3V2FPT0WU
HT-1197MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfvTpZKSzVyPUCuN|k1PiEQvF2=MnuzV2FPT0WU
CGTH-W-1NYXUfG5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTBwM{m5NVMh|ryPM1HuSHNCVkeHUh?=
KNS-42NHvkZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrFTWM2OD1yLkSwNFQ2KM7:TR?=MlPLV2FPT0WU
HuO-3N1M2jP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvZOpBpUUN3ME2wMlQxODV3IN88US=>MVPTRW5ITVJ?
VMRC-RCZNUDITI42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnKxTWM2OD1yLkSwN|A{KM7:TR?=NVvMZpprW0GQR1XS
SW954M2jSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XTNGlEPTB;MD60NFM{PSEQvF2=MX;TRW5ITVJ?
MES-SAMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvFTWM2OD1yLkSwOVA2KM7:TR?=NFPnbXpUSU6JRWK=
Ca-SkiMn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfORpBKSzVyPUCuOFA2OjRizszNMn\hV2FPT0WU
SW13MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFj2dYFKSzVyPUCuOFA3OjZizszNMl;0V2FPT0WU
NCI-H1437MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFO5UIFKSzVyPUCuOFA5ODVizszNMWjTRW5ITVJ?
U-118-MGNIXSOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rxbGlEPTB;MD60NFkxPCEQvF2=MnTJV2FPT0WU
NCI-H1734NIHXWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTtTWM2OD1yLkSyNFE{KM7:TR?=MnvCV2FPT0WU
HDLM-2NGLrTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTBwNEKwN|Mh|ryPM1Lv[XNCVkeHUh?=
AU565M320eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7HTWM2OD1yLkSyOFY5KM7:TR?=NXfQSoRGW0GQR1XS
FADUM1jQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLaTWM2OD1yLkSyOlQ6KM7:TR?=MX;TRW5ITVJ?
OS-RC-2NUDLbGxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnwTWM2OD1yLkSzNFg{KM7:TR?=MWXTRW5ITVJ?
CAMA-1NXzicGE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUGyZ4JpUUN3ME2wMlQ{PjJ4IN88US=>MYHTRW5ITVJ?
MONO-MAC-6MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXZWmQ{UUN3ME2wMlQ{QDR7IN88US=>M4rue3NCVkeHUh?=
LB831-BLCNFLOR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1SxOGlEPTB;MD60OFM4OSEQvF2=NWXJRWI1W0GQR1XS
SW982NX7USXJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXexV3BbUUN3ME2wMlQ1PTJ6IN88US=>MXvTRW5ITVJ?
SCC-3NXG0XW92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrmNmFKSzVyPUCuOFQ2PzlizszNMV\TRW5ITVJ?
C32Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELIc3lKSzVyPUCuOFUzOjlizszNNWLWeGJyW0GQR1XS
BFTC-909NGrq[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3CbnZqUUN3ME2wMlQ2Ojl7IN88US=>NIfzR5VUSU6JRWK=
MEG-01M4G3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HP[mlEPTB;MD60OVM4OyEQvF2=NInzbYpUSU6JRWK=
M14NFjGR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTBwNEW5O|kh|ryPNWXwdJFbW0GQR1XS
MPP-89MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7UdXJKSzVyPUCuOFYzPTZizszNNGjTWoRUSU6JRWK=
HCC1937MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TMR2lEPTB;MD60OlM5PCEQvF2=NGD3b|lUSU6JRWK=
SW837NHzYXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILrZ2dKSzVyPUCuOFY4OjJizszNMVLTRW5ITVJ?
DU-145NFm1UVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\ETWM2OD1yLkS2O|I6KM7:TR?=MXrTRW5ITVJ?
LB996-RCCMme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTBwNEewOVQh|ryPNV3kVphTW0GQR1XS
C8166MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwNEe0JO69VQ>?M1jOeHNCVkeHUh?=
MOLT-4NXPVXlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUf2TGR5UUN3ME2wMlQ4PzN2IN88US=>M2\Eb3NCVkeHUh?=
DMS-53NITMe3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Lz[2lEPTB;MD60O|gxQSEQvF2=NWTVUmU{W0GQR1XS
TE-5M2L3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTBwNEizNFUh|ryPMl7tV2FPT0WU
KYSE-520NXf6Z4xlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLzTWM2OD1yLkS4N|Q{KM7:TR?=M{jzOXNCVkeHUh?=
Detroit562MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1K5SGlEPTB;MD60PFg3KM7:TR?=MorRV2FPT0WU
SIMAMn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fKd2lEPTB;MD60PVQyPyEQvF2=NH;xSGpUSU6JRWK=
NCI-H1651NH;oe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnCNJdLUUN3ME2wMlQ6PjdizszNNY\yXok4W0GQR1XS
HCC1599NIHxT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTBwNEm5OVUh|ryPNX;6NFVRW0GQR1XS
ABC-1MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTBwNUC0PVYh|ryPMmm5V2FPT0WU
CAL-33NYTHPI9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7ETWM2OD1yLkWwPFQ1KM7:TR?=M4T0VXNCVkeHUh?=
OPM-2M3nPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fOfGlEPTB;MD61NFk{PyEQvF2=M4nVOHNCVkeHUh?=
RPMI-7951NVjQRoc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLpXYE5UUN3ME2wMlUxQTV5IN88US=>MVPTRW5ITVJ?
HT-1080MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHYVlVKSzVyPUCuOVEyOTlizszNMXfTRW5ITVJ?
LC4-1MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTBwNUG0NFMh|ryPM4Xvd3NCVkeHUh?=
OVCAR-3MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDTTWM2OD1yLkWxOVch|ryPMkLUV2FPT0WU
CAPAN-1M3P5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWroe|F6UUN3ME2wMlUzOjh6IN88US=>MVjTRW5ITVJ?
SK-OV-3NF;T[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NET2XlNKSzVyPUCuOVI1OzRizszNMWHTRW5ITVJ?
HuP-T3MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHmVnU2UUN3ME2wMlUzQDJ5IN88US=>NIfl[5BUSU6JRWK=
NCI-H838MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jpVmlEPTB;MD61Nlg1QSEQvF2=M3TVdHNCVkeHUh?=
K5M4LRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TWXmlEPTB;MD61N|IxOSEQvF2=MXjTRW5ITVJ?
CAL-72NYPyd3JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\ZTWM2OD1yLkWzN|g4KM7:TR?=NFmzZnNUSU6JRWK=
NH-12NGPzbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLqd4tKSzVyPUCuOVM6PTlizszNMlTKV2FPT0WU
SNB75M{XEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTqNI9KSzVyPUCuOVU4OyEQvF2=NYrzeXRmW0GQR1XS
BPH-1NGPl[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{frZmlEPTB;MD61OlM1PCEQvF2=MnG4V2FPT0WU
NOMO-1M4eySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\ocWVGUUN3ME2wMlU3Ozd{IN88US=>MlfHV2FPT0WU
G-402NXj0eZlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPTTWM2OD1yLkW2OFk6KM7:TR?=MnfIV2FPT0WU
NCI-H2052MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTBwNU[3OFEh|ryPM4XBeHNCVkeHUh?=
RCM-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XBRmlEPTB;MD61O|E3PiEQvF2=NUXPRm44W0GQR1XS
COR-L279NUPrc5BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrBc|JKSzVyPUCuOVcyQDVizszNNXfsSHk3W0GQR1XS
A253NXi1[mJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGSwSnZKSzVyPUCuOVc2OjVizszNNGW3UXFUSU6JRWK=
SK-MM-2NV7TVZpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T3RWlEPTB;MD61O|Y4QSEQvF2=MlHiV2FPT0WU
NCI-H1703NWjabHNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXv6[|FGUUN3ME2wMlU6PDJ5IN88US=>NYKyfYQ5W0GQR1XS
UACC-257MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXS0cmV6UUN3ME2wMlU6PDh5IN88US=>M17qb3NCVkeHUh?=
KALS-1M4rYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\IZ5dKSzVyPUCuOlAxOTFizszNM1vLc3NCVkeHUh?=
ES5MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTBwNkC0PEDPxE1?NEKxOW9USU6JRWK=
MHH-CALL-2NIPEc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUKzTVhlUUN3ME2wMlYxQDh6IN88US=>NHS4[ZFUSU6JRWK=
ChaGo-K-1M3Hk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXFNXFvUUN3ME2wMlYyOjJ7IN88US=>MWTTRW5ITVJ?
TGBC1TKBM{TDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jK[GlEPTB;MD62NVk5KM7:TR?=NFf6c4FUSU6JRWK=
KU-19-19Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGC4dnVKSzVyPUCuOlQ2QDZizszNMmjyV2FPT0WU
COLO-684NVGweW9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\ib3hPUUN3ME2wMlY2PjFzIN88US=>MX7TRW5ITVJ?
LS-1034NED5bGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTBwNkW4NVkh|ryPMYHTRW5ITVJ?
RT-112MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2i2WGlEPTB;MD62OlU5PyEQvF2=NX3ZRmtnW0GQR1XS
Capan-2M3rVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnyeYlvUUN3ME2wMlY3PjJ{IN88US=>NFHjUmpUSU6JRWK=
HSC-4NXO0[GNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTBwNk[2PVgh|ryPMmSyV2FPT0WU
COLO-824M372WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTneW5KSzVyPUCuOlc5OjNizszNM2LMTHNCVkeHUh?=
NCI-H2170MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDTSpdKSzVyPUCuOlgzPThizszNNVjVeYtbW0GQR1XS
GDM-1NEfsUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTBwNki0PVQh|ryPMkPZV2FPT0WU
KP-4M3P6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTBwNkm1O|Mh|ryPM4L0SnNCVkeHUh?=
VA-ES-BJM3Locmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4exU2lEPTB;MD62PVk5PiEQvF2=NELHTVNUSU6JRWK=
KM-H2MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFn4RpRKSzVyPUCuO|AxQTFizszNMoHUV2FPT0WU
HHMlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7nTWM2OD1yLkewOlYzKM7:TR?=M2XXVHNCVkeHUh?=
DK-MGM{TKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnNTWM2OD1yLkexNFE3KM7:TR?=M13MbXNCVkeHUh?=
VM-CUB-1NIW2emVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfWdHlKSzVyPUCuO|EzPTlizszNMkDQV2FPT0WU
COLO-829Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTBwN{G5PFUh|ryPM2jQ[XNCVkeHUh?=
OMC-1MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTBwN{KxNFQh|ryPMX;TRW5ITVJ?
NB12NUTLUm5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\MTWM2OD1yLkeyOVA1KM7:TR?=NYPHPYpyW0GQR1XS
NCI-H28NHHuWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHsTWM2OD1yLke0NFg{KM7:TR?=MlPTV2FPT0WU
A673MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDz[2dwUUN3ME2wMlc2OTd5IN88US=>MXLTRW5ITVJ?
LB2241-RCCM1rRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\MWGY1UUN3ME2wMlc3ODh5IN88US=>M1HLUHNCVkeHUh?=
CCRF-CEMNFXFcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\3TWM2OD1yLke3NFUzKM7:TR?=Mn7PV2FPT0WU
NCI-H510AMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETwWWxKSzVyPUCuO|cyQDZizszNNEe4U2dUSU6JRWK=
SW48NEXGRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnsV5BKSzVyPUCuO|c{OzNizszNMUXTRW5ITVJ?
NCI-H2081NFrsPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjhSI1KSzVyPUCuO|gyPDdizszNNEK3OG5USU6JRWK=
RMG-IMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXjVHNKSzVyPUCuO|gzOTJizszNMXLTRW5ITVJ?
LU-99AM2LkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrwOW1lUUN3ME2wMlc5PDF|IN88US=>MYfTRW5ITVJ?
KP-N-YSM4r4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPpbJlKSzVyPUCuO|g6OjFizszNM17wPHNCVkeHUh?=
MDA-MB-231NYrhR|VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPqVo1KSzVyPUCuPFAyOzFizszNMYnTRW5ITVJ?
U031MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTBwOEG0NlMh|ryPNH[w[GlUSU6JRWK=
EVSA-TNUm0U|drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTBwOEG2O|Ih|ryPMWXTRW5ITVJ?
MDA-MB-157M4LkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLhO3dKSzVyPUCuPFIzPzFizszNNH7yVYxUSU6JRWK=
EHEBNY\QUmY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITYVJFKSzVyPUCuPFIzPzZizszNNV7GN|dDW0GQR1XS
KINGS-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\vb2lEPTB;MD64NlU2PSEQvF2=M1roSHNCVkeHUh?=
23132-87NGf5TWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkiyTWM2OD1yLkiyPFQ{KM7:TR?=MkXuV2FPT0WU
EFO-21M{HTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvvTWM2OD1yLki0NFg6KM7:TR?=MVXTRW5ITVJ?
DOKMoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV71TmJLUUN3ME2wMlg1QCEQvF2=M3HLcXNCVkeHUh?=
NCI-H2171M1PydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPDUpdKSzVyPUCuPFQ6PiEQvF2=MVPTRW5ITVJ?
NCI-SNU-5M3yybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1ryZ2lEPTB;MD64OVU4KM7:TR?=Mm\KV2FPT0WU
SK-N-DZNXLSbWlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HSR2lEPTB;MD64OVk1OyEQvF2=NFXzR2JUSU6JRWK=
SNU-C2BM1;1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fFR2lEPTB;MD64OlgxOSEQvF2=MWrTRW5ITVJ?
CP66-MELNIXQblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\xZWlEPTB;MD64O|EyKM7:TR?=MojaV2FPT0WU
SN12CNG\WRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHz0fIlKSzVyPUCuPFg3OzdizszNNGm3RWFUSU6JRWK=
A172MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljqTWM2OD1yLki4Olk5KM7:TR?=MYXTRW5ITVJ?
NCI-H2347M2q0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTBwOEi3OVMh|ryPMmTrV2FPT0WU
NCI-H2228NGrVNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\JTWM2OD1yLki5N|M6KM7:TR?=MWPTRW5ITVJ?
SNU-387MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3BeVlKSzVyPUCuPVAzPjRizszNNUW0eXoyW0GQR1XS
SK-MEL-24MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Ky[2lEPTB;MD65NVM1PCEQvF2=M3XrdHNCVkeHUh?=
MDA-MB-468MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTBwOUG3N{DPxE1?M2Gyd3NCVkeHUh?=
NCI-H1694Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXSVFFKSzVyPUCuPVE5PzZizszNMYTTRW5ITVJ?
CCF-STTG1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTBwOUK2N|ch|ryPNHP3[WVUSU6JRWK=
K052MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnPdXd[UUN3ME2wMlk1ODR5IN88US=>NVj4XGxKW0GQR1XS
NCI-H446NXTOfYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIGxbJdKSzVyPUCuPVUxOSEQvF2=NF7wNFVUSU6JRWK=
MFE-280M2LDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLwOYZHUUN3ME2wMlk3OjlzIN88US=>M1X0VnNCVkeHUh?=
KU812NUfST4JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXncGhKSzVyPUCuPVk{QDlizszNNEjLZ5dUSU6JRWK=
MDA-MB-361M2LhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTBwOUm3O|ch|ryPMUjTRW5ITVJ?
RajiMmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17xdWlEPTB;MT6wNlI3PyEQvF2=Moq3V2FPT0WU
TE-6NGnzR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHM[3dKSzVyPUGuNFM2PjZizszNNV7kWnNXW0GQR1XS
CAL-148NUDWfZRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLNPJlIUUN3ME2xMlA1PDR|IN88US=>MUfTRW5ITVJ?
NCI-H1963Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTFwMES1OVMh|ryPMYXTRW5ITVJ?
SK-N-ASM{nRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlX0TWM2OD1zLkC0Olg2KM7:TR?=MlLCV2FPT0WU
RERF-LC-MSM4K3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTFwME[zOFkh|ryPM{fzR3NCVkeHUh?=
BENMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDuSlhKSzVyPUGuNFcyOzdizszNNX\LdZJ6W0GQR1XS
CAS-1MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFwMEmxNlMh|ryPMoWyV2FPT0WU
SW780MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTFwMEmxPFEh|ryPM1TmUHNCVkeHUh?=
LU-65NFvzSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTFwMEm0NUDPxE1?M4[y[nNCVkeHUh?=
D-283MEDM{myd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTFwMUKyO|Ih|ryPNWfZUW1[W0GQR1XS
HCC2157Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF74cHlKSzVyPUGuNVM3PDJizszNMl7jV2FPT0WU
RCC10RGBMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHIWnZKSzVyPUGuNVQxODZizszNMkDhV2FPT0WU
PLC-PRF-5MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfUeYRKSzVyPUGuNVUzOjlizszNMmLJV2FPT0WU
H4MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7Yfm5KSzVyPUGuNVU1OzlizszNM{nzTnNCVkeHUh?=
TURNHHrTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkX0TWM2OD1zLkG1O|UzKM7:TR?=MVLTRW5ITVJ?
NCI-H2141M3fTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrCTWM2OD1zLkG4PVQ3KM7:TR?=MYLTRW5ITVJ?
PFSK-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfXZmFKSzVyPUGuNlA2OzJizszNMX\TRW5ITVJ?
SK-MEL-28M2X0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTFwMkOyNlEh|ryPNGWwUZlUSU6JRWK=
SCC-9NXLuVnVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mki2TWM2OD1zLkKzOlY2KM7:TR?=MnvaV2FPT0WU
T47DM3;Mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXxN3RKSzVyPUGuNlM3QTZizszNMX;TRW5ITVJ?
TCCSUPNUPPTm5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3HTWM2OD1zLkK1NFI6KM7:TR?=NHrLS2tUSU6JRWK=
SU-DHL-1MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;tfopZUUN3ME2xMlI2OTF6IN88US=>NEPMRmRUSU6JRWK=
HL-60NUHwPZZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTFwMkW1PFgh|ryPMVjTRW5ITVJ?
NCI-H1436MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jX[2lEPTB;MT6yOlE1QSEQvF2=NEnmS2xUSU6JRWK=
DMS-114Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHzTWM2OD1zLkK2OlMzKM7:TR?=NYXFPHpoW0GQR1XS
BOKUMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrvRWc{UUN3ME2xMlI5ODl3IN88US=>Mlq0V2FPT0WU
MS-1NXS2RpZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPHem9WUUN3ME2xMlI6ODZ7IN88US=>Mn3NV2FPT0WU
NCI-H661Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFwM{C0O|gh|ryPNHfyfIRUSU6JRWK=
HT-3MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7PbJJKSzVyPUGuN|A2OjlizszNNV3Qenc1W0GQR1XS
CAL-54NGTvS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTFwM{C3NlUh|ryPM4PnSHNCVkeHUh?=
SW1463MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7VTW9KSzVyPUGuN|E5PzJizszNNXfLWJVUW0GQR1XS
COLO-668M{\2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DvSGlEPTB;MT6zN|A2PiEQvF2=NU\yelEyW0GQR1XS
PANC-08-13Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzMe5FvUUN3ME2xMlM{QDB|IN88US=>NFL3blVUSU6JRWK=
BB49-HNCMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XRSmlEPTB;MT6zOFAyKM7:TR?=Ml;SV2FPT0WU
M059JM2\hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPtcFFqUUN3ME2xMlM2QDN{IN88US=>NHv6[GFUSU6JRWK=
NCCITNHrtN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTFwM{e5PFgh|ryPMmXPV2FPT0WU
LN-405MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTFwM{myOlQh|ryPMlrLV2FPT0WU
UMC-11MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDobGpKSzVyPUGuN|k6QTZizszNNIHROWhUSU6JRWK=
NB5NYDCO5pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfpTWM2OD1zLkSxNlI4KM7:TR?=MX3TRW5ITVJ?
TE-441-TM2jVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTFwNEK4NVch|ryPMVjTRW5ITVJ?
ME-180NVLsSHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTEVHhXUUN3ME2xMlQ1Ozl{IN88US=>NIfa[ZFUSU6JRWK=
HCC70MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTFwNE[wPVYh|ryPMoC0V2FPT0WU
no-10NGn5Z2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUC5VIdUUUN3ME2xMlQ3OThzIN88US=>NGTZUpVUSU6JRWK=
JEG-3NWTsXG1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\2RW1KSzVyPUGuOVAyOzJizszNMnvlV2FPT0WU
no-11MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTzRWY5UUN3ME2xMlUxQDh{IN88US=>MnfJV2FPT0WU
CHP-126M{DNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;VXGlEPTB;MT61OlY6OSEQvF2=MnvrV2FPT0WU
EGI-1NGTRTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;H[YFKSzVyPUGuOVgxOjVizszNMlnHV2FPT0WU
D-392MGNFf1eJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;EdGlEPTB;MT61PVY{KM7:TR?=MmTRV2FPT0WU
RT4NUnKc2g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTEXlhKSzVyPUGuOVk3OzdizszNNYGxSW9[W0GQR1XS
A204M3vrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTFwNUm4NFEh|ryPM13xS3NCVkeHUh?=
NCI-H1304MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTFwNkO1PVEh|ryPMXzTRW5ITVJ?
BeckerM1zDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTFwNkSyOFEh|ryPNE\2OXVUSU6JRWK=
OE19MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHq[JBEUUN3ME2xMlY2PTF6IN88US=>MVXTRW5ITVJ?
EKVXNXr2dVg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLwNlBZUUN3ME2xMlY2PjF6IN88US=>M1nDbnNCVkeHUh?=
KLENGjlWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DyNGlEPTB;MT62OVcyPCEQvF2=NWewRXpuW0GQR1XS
K-562MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHhXpljUUN3ME2xMlY4ODN5IN88US=>NIrsV3RUSU6JRWK=
MDA-MB-175-VIINEXM[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDiVXFKSzVyPUGuOlg6QTdizszNMojqV2FPT0WU
NCI-H716M33Z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fsdmlEPTB;MT62PVMxPCEQvF2=M{TK[nNCVkeHUh?=
Caov-3MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nMW2lEPTB;MT62PVQyOyEQvF2=NYrPWlhTW0GQR1XS
HCC1187M365O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXX2d2xWUUN3ME2xMlcxPTR3IN88US=>NV3C[4xuW0GQR1XS
CAKI-1MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzPTWM2OD1zLkeyNlkzKM7:TR?=NYnKU3ZYW0GQR1XS
MOLT-16MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nhU2lEPTB;MT63N|MxPyEQvF2=M1LMNXNCVkeHUh?=
PC-3M37xfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrRSpRxUUN3ME2xMlc2ODhizszNNF:0PZJUSU6JRWK=
DV-90NInoWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfPTWM2OD1zLke1OVg2KM7:TR?=MofzV2FPT0WU
RXF393NEP5N2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vSe2lEPTB;MT63O|I6PCEQvF2=MXnTRW5ITVJ?
SK-NEP-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYn4XmFUUUN3ME2xMlgzOzN7IN88US=>M1vnXHNCVkeHUh?=
HCC1419MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\EblZKSzVyPUGuPFI3QTJizszNNIP5XGNUSU6JRWK=
BV-173MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFv4NmZKSzVyPUGuPFI6QTVizszNMnT6V2FPT0WU
MKN7M4fOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XCOmlEPTB;MT64PVIzKM7:TR?=NHqx[lRUSU6JRWK=
LAN-6MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHTTWM2OD1zLki5OVU{KM7:TR?=NEnOeHVUSU6JRWK=
Mo-TMnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLETWM2OD1zLkmwNFM6KM7:TR?=NHLOcmFUSU6JRWK=
HCC1395MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jqPGlEPTB;MT65Nlg3OyEQvF2=NYH1doZvW0GQR1XS
HC-1M13RV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTFwOUO0O{DPxE1?M4LFd3NCVkeHUh?=
HPAF-IIMkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXBTYFUUUN3ME2xMlk1PDF6IN88US=>MWnTRW5ITVJ?
CPC-NNHe4To9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TTfGlEPTB;MT65PFAxOiEQvF2=NF;vfnRUSU6JRWK=
MKN45MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7FPZdyUUN3ME2xMlk6OTF7IN88US=>M4PYfnNCVkeHUh?=
NCI-H1693Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rvU2lEPTB;Mj6wNFQ{OyEQvF2=M2fWPXNCVkeHUh?=
SHP-77MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHqVllKSzVyPUKuNFA2OzNizszNNXLmPFc3W0GQR1XS
NCI-H1522NI\uWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HlWGlEPTB;Mj6wNVczPCEQvF2=MoDuV2FPT0WU
SW1573MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nlS2lEPTB;Mj6wNlIh|ryPM{\6[HNCVkeHUh?=
DBTRG-05MGNG\jRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTJwME[wPFch|ryPMWTTRW5ITVJ?
SCC-4NWTQ[HZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUT3Um1YUUN3ME2yMlE1OzFizszNNUH0NoRHW0GQR1XS
DMS-153M1XCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTJwMU[2Olgh|ryPMYjTRW5ITVJ?
MDA-MB-415NVHEc3BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjjU2duUUN3ME2yMlE4PTJizszNNULqdXQ{W0GQR1XS
NCI-H2126NHjzT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mly2TWM2OD1{LkKyPFg5KM7:TR?=MoHmV2FPT0WU
MDA-MB-453MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\zfHJyUUN3ME2yMlI{OzJizszNNITNZ4lUSU6JRWK=
U-87-MGMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjQVnM3UUN3ME2yMlI5PTl{IN88US=>Mn3SV2FPT0WU
LNCaP-Clone-FGCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHqxfmtKSzVyPUKuN|AyODJizszNNHL6ZVVUSU6JRWK=
NCI-H1581M1T5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTJwM{KxNFUh|ryPNUjOT2xUW0GQR1XS
BC-3M4C2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HLeGlEPTB;Mj6zOlUxQSEQvF2=NYnUSGdoW0GQR1XS
HCC38MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXzTWM2OD1{LkO4OFQ4KM7:TR?=NVnYfHMyW0GQR1XS
HCC2218NXXycGZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHznWZZKSzVyPUKuOFA5ODlizszNNFvj[ZRUSU6JRWK=
RO82-W-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7xPFM5UUN3ME2yMlQyOjVizszNNGPxbllUSU6JRWK=
C2BBe1M37UOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPPbXNKSzVyPUKuOFE2PzhizszNMmPlV2FPT0WU
LAMA-84NWLCeJNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rDOGlEPTB;Mj61O|M3QCEQvF2=NYHjU5F[W0GQR1XS
GMS-10M{\qSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHOTWM2OD1{LkW3OlEyKM7:TR?=M3\4VXNCVkeHUh?=
GCTNFjLW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTJwNUi2PVQh|ryPM1rGOnNCVkeHUh?=
SK-CO-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jLWWlEPTB;Mj62NVY3KM7:TR?=NUThSXBJW0GQR1XS
NCI-H526NF64WmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLSSmdKSzVyPUKuOlM1PSEQvF2=MYPTRW5ITVJ?
SW1088MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PscmlEPTB;Mj63O|g{QSEQvF2=MmjaV2FPT0WU
HT55MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fUbmlEPTB;Mj63PFY6PSEQvF2=NYjkXYxVW0GQR1XS
NB10MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2W3emlEPTB;Mj64NVc1QCEQvF2=MlP5V2FPT0WU
UACC-893NHnVVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTJwOEW3OFkh|ryPM2TKWXNCVkeHUh?=
NCI-H1618MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFSyUIFKSzVyPUKuPFgyPTNizszNNIXufnpUSU6JRWK=
NCI-H1092M2LQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2[wNWlEPTB;Mz6wO|gyOiEQvF2=MmOwV2FPT0WU
SBC-1NFK0PIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLqTWM2OD1|LkC4OVU{KM7:TR?=NFLHb|RUSU6JRWK=
NCI-H1623MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXi4eodkUUN3ME2zMlA6OzRizszNNITtV4NUSU6JRWK=
SiHaNWDJUIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITx[YtKSzVyPUOuNVE6PzdizszNM4j1bnNCVkeHUh?=
D-263MGMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTNwMUS3PFgh|ryPMlHHV2FPT0WU
NCI-H1573MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HWfGlEPTB;Mz6xPVY1OSEQvF2=M3vEW3NCVkeHUh?=
NCI-H82M4naSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M165d2lEPTB;Mz6zOFQ{QSEQvF2=NVu2fXFZW0GQR1XS
NCI-H2196NGDVO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFT2dmZKSzVyPUOuN|UxODhizszNNVPhOoZMW0GQR1XS
MFM-223Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPxZlRKSzVyPUOuN|c{PTFizszNM1T6NXNCVkeHUh?=
COLO-678NU\Nc49bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTNwM{ixPFYh|ryPM3HWfHNCVkeHUh?=
EW-3M375VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTNwNEC5OUDPxE1?MljhV2FPT0WU
MHH-NB-11MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnz2TWM2OD1|LkS0NFY6KM7:TR?=NX3aZ3RZW0GQR1XS
EM-2Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLJTWM2OD1|Lk[zPVgh|ryPNUXKSpp{W0GQR1XS
FTC-133MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTNwNkW0OVgh|ryPNX2xUXBUW0GQR1XS
NCI-H209NFHVUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXpSZBKSzVyPUOuOlc3PTNizszNMWPTRW5ITVJ?
TGBC24TKBNUfjfXV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTNwNkizOVUh|ryPMXHTRW5ITVJ?
LC-1FMl\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TtWmlEPTB;Mz63NVc3PCEQvF2=NXy3VYVDW0GQR1XS
C-4-IINYnDPXRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTNwN{W2OFMh|ryPMl\yV2FPT0WU
NCI-H1650Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYCxdHBJUUN3ME2zMlc5PDV3IN88US=>MoDjV2FPT0WU
JVM-2NULzV2c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Xq[GlEPTB;Mz65N|Y{QSEQvF2=MoPnV2FPT0WU
CaR-1NGLJXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVP2dYs1UUN3ME2zMlk4PjF5IN88US=>Mn;JV2FPT0WU
MDA-MB-134-VIM1nlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfWNotqUUN3ME20MlAzQTV{IN88US=>NEfsfoVUSU6JRWK=
NCI-H719NUPmXYNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTieHN1UUN3ME20MlE2Ozh6IN88US=>NGrpS4hUSU6JRWK=
GOTONG\Hb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETC[Y9KSzVyPUSuNlk4ODVizszNMXLTRW5ITVJ?
NCI-N87NFXNbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfCTWM2OD12LkO4PFIyKM7:TR?=MX7TRW5ITVJ?
NB6Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LvTWlEPTB;ND60NlUxQSEQvF2=NWPBRXpiW0GQR1XS
DSH1M2HBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LzcGlEPTB;ND60O|EyPiEQvF2=MnPRV2FPT0WU
BT-20M4XiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnxbHFKUUN3ME20MlQ6ODB{IN88US=>NFXybHdUSU6JRWK=
NCI-H1882MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnuXVlKSzVyPUSuOVA2PyEQvF2=NYn0fW0xW0GQR1XS
WM-115MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\w[|ZPUUN3ME20MlUxQDhzIN88US=>NFX5em9USU6JRWK=
SKG-IIIaMlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTXTWM2OD12Lk[3O|ch|ryPM{jrRnNCVkeHUh?=
NCI-H69NEnpTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXmxNIIxUUN3ME20MlcxOjd3IN88US=>MYjTRW5ITVJ?
MSTO-211HMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTRwOEO1OlUh|ryPNXHVdo9EW0GQR1XS
MewoMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTRwOU[zNVMh|ryPMoLmV2FPT0WU
GI-ME-NNV\aWXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTVwMEC1NFkh|ryPNEPGTJFUSU6JRWK=
T98GM1nCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfoeXNKSzVyPUWuNFY2ODhizszNNHfoZ4pUSU6JRWK=
ECC4MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLvSG9DUUN3ME21MlA6Ozd{IN88US=>NXzQZnJiW0GQR1XS
EW-11NILpd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTVwMUiwPVkh|ryPNULRd4wyW0GQR1XS
COLO-800NGqwfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXxcndKSzVyPUWuNVk{PDlizszNNUH3NVZSW0GQR1XS
NCI-H1755NYDGdnlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTVwMkOwNlch|ryPMVrTRW5ITVJ?
KMS-12-PEM3fMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHXXIZVUUN3ME21MlM2ODh3IN88US=>NInq[lNUSU6JRWK=
HCC1954NWPiPIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\lS2lEPTB;NT64OVk4OSEQvF2=NFzsTmpUSU6JRWK=
NCI-H187MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTVwOUK5PFkh|ryPMkW3V2FPT0WU
LU-165NHXV[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3z4[WlEPTB;NT65PVAxOiEQvF2=MnvBV2FPT0WU
YAPCNV:xPVM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTVwOUmwOlgh|ryPNYHOXWl{W0GQR1XS
LU-139M{\VT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGryWHdKSzVyPU[uNFg{PjhizszNM1v3eHNCVkeHUh?=
D-502MGNEPkclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH:4fY9KSzVyPU[uN|IxPDdizszNNWX2R2w1W0GQR1XS
IST-SL1NELrN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TY[WlEPTB;Nj61N|k1QCEQvF2=MVPTRW5ITVJ?
DG-75NYrmNlZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nzcWlEPTB;Nj64PFc5PiEQvF2=MlnXV2FPT0WU
NCI-H1155NUHoZZVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTZwOUW1PFEh|ryPMlT0V2FPT0WU
EFE-184MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTdwM{G2PVUh|ryPMWTTRW5ITVJ?
AsPC-1NUDBRlBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTdwNEi4NFch|ryPMkHMV2FPT0WU
SW948MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTvPHdKSzVyPUeuOVg{QTVizszNMUDTRW5ITVJ?
NCI-H524NUHOXopXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTlwNUi2Nlgh|ryPNIPIeYJUSU6JRWK=
KOSC-2Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTlwNkK4N|Qh|ryPMWjTRW5ITVJ?
T-24NFThU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NID1VVhKSzVyPUmuPVQ1OTVizszNNEG0eYhUSU6JRWK=
NCI-H748M2fQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXp[G5KSzVyPUGwMlY{QTdizszNMWjTRW5ITVJ?
NCI-H23M1riTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TpUmlEPTB;MUCuOlQ1OiEQvF2=NHf4b|BUSU6JRWK=
UACC-812NUO3TYNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXvO4hKSzVyPUGxMlcyPyEQvF2=MlnPV2FPT0WU
SCLC-21HMl;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXwTWM2OD1zMj6xOVUyKM7:TR?=NUfvW2J2W0GQR1XS
NCI-SNU-16NVXHcFhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELVPY5KSzVyPUGzMlEzPThizszNM1TOU3NCVkeHUh?=
HD-MY-ZM1\RWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTF2Lk[zOlMh|ryPNH7LS4RUSU6JRWK=
SK-N-FIM3vDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7VS5BKSzVyPUG0Mlg6OTJizszNMmPtV2FPT0WU
LB647-SCLCNEnoWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TmUWlEPTB;MUWuO|E6PSEQvF2=MmfXV2FPT0WU
NCI-H345NXP2VoZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTF5LkO0N{DPxE1?M2KwdXNCVkeHUh?=
NCI-H1563NHn1UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;qTWM2OD1zOD63OlAyKM7:TR?=NGHQeGRUSU6JRWK=
RLMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PwXWlEPTB;MkGuNlY2PiEQvF2=NV7iO|VQW0GQR1XS
KY821MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXSTWM2OD1{Mj6wOVU{KM7:TR?=NF7vNZpUSU6JRWK=
JVM-3MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\ZTWM2OD1{NT6wOFE{KM7:TR?=NHjBVWpUSU6JRWK=
NCI-H1793MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTJ6LkW0PVkh|ryPNGj6Z25USU6JRWK=
LU-134-AMmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnPW3ZKSzVyPUOwMlIxOzdizszNM{fLfXNCVkeHUh?=
NCI-H1395M3T1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTN{LkK0N|Eh|ryPNXPBXpllW0GQR1XS
NCI-H1993MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPxXI5[UUN3ME2zNk45OjF6IN88US=>NIPFXlJUSU6JRWK=
P31-FUJMluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmP3TWM2OD1|Mz60PFk6KM7:TR?=MXPTRW5ITVJ?
LS-513NFXDfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDKOlVKSzVyPUO1Mlg5PzlizszNMmHYV2FPT0WU
SK-MEL-1NEXiSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPWTWM2OD12MD6zOFk6KM7:TR?=NXzWZWN5W0GQR1XS
SW684NHS3b3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTR|Lkm2OlEh|ryPMlLlV2FPT0WU
COR-L88Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTR2LkC2OlUh|ryPNEXpOJBUSU6JRWK=
NCI-H889MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTR3LkCwPFch|ryPNYn4N|BlW0GQR1XS
TALL-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTR4LkGxPVkh|ryPMV\TRW5ITVJ?
KARPAS-299MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mof2TWM2OD12Nz6xPVk{KM7:TR?=NU\qTmtrW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Protocol(Only for Reference)

Kinase Assay: [1]

Bcl-2 Binding affinity calculation A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.

Cell Assay: [2]

Cell lines Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
Concentrations ~10 μM
Incubation Time 48-72 hours
Method Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.

Animal Study: [1]

Animal Models Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
Formulation Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
Dosages 0.0313, 0.25, 0.5 and 2 mg/kg
Administration Administered intravenously (tail vein) once a day

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Nguyen M, et al. Proc Natl Acad Sci, 2007, 104(49), 19512-191517.

[2] Trudel S, et al. Blood, 2009, 113(2), 299-305.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymp  ...more Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|  ...more Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00719901 Terminated Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma National Cancer Institute (NCI) July 2008 Phase 1|Phase 2

view more

Chemical Information

Download Obatoclax Mesylate (GX15-070) SDF
Molecular Weight (MW) 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 83 mg/mL (200.73 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (Z)-2-(5-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-4-methoxy-5H-pyrrol-2-yl)-1H-indole mesylate

Customer Product Validation(9)


Click to enlarge
Rating
Source Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Immunohistochemical staining
Cell Lines Mice
Concentrations 3 mg/kg
Incubation Time 3 weeks
Results Tumors from 3 mice in each group were analyzed with H&E and immunohistochemical staining. Interestingly, H&E staining revealed substantially increased necrosis in the tumors for GX15-070 treated groups compared to the vehicle control group, especially for the combination (AZD2281 and GX15-070) group.

Click to enlarge
Rating
Source Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Electron microscopic morphology
Cell Lines T1682 cells
Concentrations 100, 1000 nM
Incubation Time 1, 6, 48 h
Results Gx15-070 treatment of TET cells leads to both growth inhibition and cell death. Gx15-070 induces autophagy-dependent necroptosis in acute lymphoblastic leukemia cells, it's performed electron microscopy (EM) in TET cells, which demonstrated changes in mitochondrial structure as early signs of autophagy after 1 h Gx15-070 treatment. After 6 h treatment, cytoplasmic vacuolization and mitochondrial swelling with early signs of necroptotic cell death were evident. Intriguingly, cytoplasmic vacuolization, late-stage necroptotic or autophagic cell death were the main features 48 h after Gx15-070 (1 uM) treatment.

Click to enlarge
Rating
Source Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Western blot
Cell Lines T1682 cells
Concentrations 100, 250, 500, 1000 nM
Incubation Time 6 h
Results Gx15-070 induced a progressive reduction of AKT Ser473 and Thr308 phosphorylation and a reduction of p-RPS6 phosphorylation, suggesting inhibition of mTOR pathway, in line with previous reports. Moreover, Gx15-070 induced phosphorylation of AMPKα, a Ser/Thr kinase normally activated when ATP level is reduced.AMPK phosphorylation and LC3B cleavage appeared within 1 h after Gx15-070 treatment.

Click to enlarge
Rating
Source Cell death dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Viability assay
Cell Lines BM3.3 CD8 T cells
Concentrations 0.1-10uM
Incubation Time
Results T-cell activation induced resistance to Bcl-2 inhibition by ABT-737 (no binding of A1 and Mcl-1) and by Antimycin A (no binding of A1 only), but had no impact on the proapoptotic potency of the pan-Bcl-2 inhibitor obatoclax.

Click to enlarge
Rating
Source Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Immunostaining
Cell Lines HUH6 cells
Concentrations 0.1, 0.3 uM
Incubation Time 24 h
Results In HUH6 cells mitochondria with an intact membrane potential were observed in the JC-1 staining in both, control and TNF-a treated cultures (C, D). The number of reddish points indicating active mitochondria decreased when the HUH6 cells were treated with obatoclax and decreased even further when the treatment was performed in combination with TNF-a, which reflects the breakdown of mitochondrial membranes decreased aggregation of JC-1. This was concentration dependent (E-H).

Click to enlarge
Rating
Source BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Cell proliferation assays
Cell Lines SET-2 cells
Concentrations 1-10000 nM
Incubation Time 72 h
Results Incubation of SET-2 cells with sub-optimal concentrations of the pan-Bcl-2 family protein inhibitor obatoclax in cell proliferation assays lowered the GI 50 of NVP-BSK805 by 3 to 4 fold.

Click to enlarge
Rating
Source Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Clonogenic survival assay
Cell Lines MEF cells
Concentrations 0-300 ng/mL
Incubation Time 24 h
Results

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Hoechst staining
Cell Lines MDB-MA-231 cells
Concentrations 1 μM
Incubation Time
Results

Click to enlarge
Rating
Source Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Cell Viability/Western Blot
Cell Lines Nalm-6 ABT-R cells
Concentrations 5-10 uM
Incubation Time 18 h
Results Nalm-6 ABT-R cells were sensitive to obatoclax; however, Nalm-6 cells were equally sensitive (IC50: 10 umol/L). Reh parental cells (IC50: 5umol/L) were also more sensitive to obatoclax compared with ABT-R cells, as measured by trypan blue exclusion. Mcl-1 protein levels were downregulated following obatoclax treatment. NOXA levels also increased, however these changes did not correlate with cell death.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcl-2 Products

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • TW-37

    TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

  • Sabutoclax

    Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Recently Viewed Items

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us